Abstract
With respect to patient safety and long-term efficacy, immunogenicity of therapeutic antibodies remains an important issue. Pre-treatment of samples using either higher temperature or acidification in order to separate drug/anti-drug antibody complexes has been implemented in the traditional bridging assay and an in-house-developed affinity capture elution assay but only a limited drug tolerance was obtained. In this study, we aim to apply a drug-resistant anti-drug antibody assay to adalimumab through a combination of adalimumab/anti-adalimumab antibody complex precipitation and acid dissociation. A linear dose–response curve ranging from 3.1 to 200 ng/mL was obtained in 1/125 diluted serum, allowing detection of anti-adalimumab antibody concentrations up to 25 μg/mL equivalents MA-ADM6A10, a calibrator anti-adalimumab antibody. The cut-off point for detection was determined using 16 samples of adalimumab naïve patients and set at 0.39 μg/mL equivalents. Validation of the assay revealed that no detectable anti-adalimumab antibody concentrations were found in samples with either a positive anti-infliximab antibody concentration, a physiologic concentration of TNFα, or a high concentration of rheumatoid factor. Full recoveries were obtained when various concentrations of adalimumab (0, 1, 10, and 50 μg/mL) were spiked to 1, 2, and 4 μg/mL of MA-ADM6A10. Spiking of 50 μg/mL adalimumab to eight individual sera revealed similar anti-adalimumab antibody concentrations as in the absence of adalimumab, with a Pearson r correlation of 0.99 and an interclass correlation of 0.99. The assay allows accurate evaluation of adalimumab immunogenicity during induction or upon dose intensification and in serum samples not taken at trough.
Similar content being viewed by others
Abbreviations
- ADA:
-
Anti-drug antibody
- ELISA:
-
Enzyme-linked immunosorbent assay
- HRP:
-
Horse radish peroxidase
- IBD:
-
Inflammatory bowel disease
- ICC:
-
Intra-class correlation coefficient
- MA-ADM:
-
Monoclonal antibody against adalimumab
- MA-IFX:
-
Monoclonal antibody against infliximab
- OD:
-
Optical density
- PEG:
-
Polyethylene glycol
- TNFα:
-
Tumor necrosis factor-alpha
References
West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PCF, Van Der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2008;28(9):1122–6. doi:10.1111/j.1365-2036.2008.03828.x.
Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies. Landes Biosci. 2010;2(3):256–65.
van Schouwenburg PA, Kruithof S, Votsmeier C, van Schie K, Hart MH, de Jong RN, et al. Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J Biol Chem. 2014;289(50):34482–8. doi:10.1074/jbc.M114.615500.
van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EEL, Kruithof S, de Groot E, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2012;104–9. doi: 10.1136/annrheumdis-2012-201445.
van Schouwenburg PA, Krieckaert CL, Rispens T, Aarden L, Wolbink GJ, Wouters D. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis. 2013;72:1680–6. doi:10.1136/annrheumdis-2012-202407.
Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 2006;24(6):274–80. doi:10.1016/j.tibtech.2006.04.001.
Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 2014;11(4):243–55. doi:10.1038/nrgastro.2013.253.
Bendtzen K. Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection. Front Immunol. 2015;6(4):1–5. doi:10.3389/fimmu.2015.00109.
Gils A, Vande Casteele N, Poppe R, Van de Wouwer M, Compernolle G, Peeters M, et al. Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization. Ther Drug Monit. 2014;0(0):1–5. doi: 10.1097/FTD.0000000000000074.
van Schouwenburg PA, Kruithof S, Wolbink G, Wouters D, Rispens T. Using monoclonal antibodies as an international standard for the measurement of anti-adalimumab antibodies. J Pharm Biomed Anal. 2016;120:198–201. doi:10.1016/j.jpba.2015.12.040.
van Stappen T, Billiet T, Vande Casteele N, Compernolle G, Brouwers E, Vermeire S, et al. An optimized anti-infliximab bridging enzyme-linked immunosorbent assay for harmonization of anti-infliximab antibody titers in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21(9):2172–7. doi:10.1097/MIB.0000000000000434.
van Stappen T, Brouwers E, Vermeire S, Gils A. Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay. Drug Test Anal. 2016. doi:10.1002/dta.1968.
Bourdage JS, Cook CA, Farrington DL, Chain JS, Konrad RJ. An affinity capture elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods. 2007;327(1–2):10–7. doi:10.1016/j.jim.2007.07.004.
Zoghbi J, Xu Y, Grabert R, Theobald V, Richards S. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays. J Immunol Methods. 2015;426:62–9. doi:10.1016/j.jim.2015.08.002.
Grabert R, Richards S, Theobald V, Xu YX, Zoghbi J. Assays for detecting the presence or amount of an anti-drug antibody. WO 2015123315 A1. 2015, https://www.google.com/patents/WO2015123315A1?cl=en. Accessed 4 November 2016.
Vande Casteele N, Ballet V, Van Assche G, Rutgeerts P, Vermeire S, Gils A. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut. 2012;61:321. doi:10.1136/gut.2010.236869.
Bian S, Stappen TV, Baert F, Compernolle G, Brouwers E, Tops S, et al. Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays. J Pharm Biomed Anal. 2016;125:62–7. doi:10.1016/j.jpba.2016.03.029.
Wang SL, Hauenstein S, Ohrmund L, Shringarpure R, Salbato J, Reddy R, et al. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal. 2013;78–79:39–44. doi:10.1016/j.jpba.2013.01.031.
van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patients. J Immunol Methods. 2010;362(1–2):82–8. doi:10.1016/j.jim.2010.09.005.
Kelley M, Ahene AB, Gorovits B, Kamerud J, King LE, McIntosh T, et al. Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation. AAPS J. 2013;15(3):646–58. doi:10.1208/s12248-013-9468-4.
Dai S, Schantz A, Clements-Egan A, Cannon M, Shankar G. Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity. AAPS J. 2014;16(3):464–77. doi:10.1208/s12248-014-9581-z.
Acknowledgments
This study was financially supported in part grants IOF/KP/12/002 and C22/15/025 from the KU Leuven. SB acknowledges the China Scholarship Council (CSC) for the scholarship. Marc Ferrante is a Senior Clinical Investigator of the Research Foundation—Flanders (FWO), Belgium.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
MF receives financial support for research from Takeda, lecture fees from Tillotts, Ferring, Boehringer-Ingelheim, Janssen, Chiesi, Falk, Zeria, Mitsubishi Tanabe, MSD, Takeda, and Abbvie and does consultancy for Abbvie, Ferring, MSD, Boehringer-Ingelheim, and Janssen. AG has served as a speaker for MSD, Janssen Biologicals, Pfizer, and Abbvie; as consultant for UCB; and has received Investigator Initiated Research Grants from Pfizer. KU Leuven licensed infliximab and adalimumab ELISA to apDia. SB declares not to have a conflict of interest.
Rights and permissions
About this article
Cite this article
Bian, S., Ferrante, M. & Gils, A. Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of Adalimumab. AAPS J 19, 468–474 (2017). https://doi.org/10.1208/s12248-016-0018-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-016-0018-8